Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;39(12):1081-1087.
doi: 10.1097/INF.0000000000002838.

Treatment and Outcomes of Children With Febrile Urinary Tract Infection Due to Extended Spectrum Beta-lactamase-producing Bacteria in Europe: TOO CUTE Study

Konstantinos Vazouras  1   2 , Yingfen Hsia  1   3 , Laura Folgori  1   4 , Julia Bielicki  1   5 , Elise Aguadisch  6 , Alasdair Bamford  7 , Ana Brett  8 , Marion Caseris  9 , Rimante Cerkauskiene  10 , Maia De Luca  11 , Elias Iosifidis  12 , John Kopsidas  2 , Ángela Manzanares  13 , Tim Planche  14 , Andrew Riordan  15 , Tina Plankar Srovin  16 , Ana Isabel Valdivielso Martínez  17 , Eleni Vergadi  18 , Mike Sharland  1 , Romain Basmaci  6   19
Affiliations
Free article

Treatment and Outcomes of Children With Febrile Urinary Tract Infection Due to Extended Spectrum Beta-lactamase-producing Bacteria in Europe: TOO CUTE Study

Konstantinos Vazouras et al. Pediatr Infect Dis J. 2020 Dec.
Free article

Abstract

Background: The prevalence of extended-spectrum beta-lactamase producing Εnterobacteriaceae (ESBL-PE) is increasing globally. ESBL-PE are an important cause of urinary tract infections (UTIs) in children. We aimed to characterize the clinical presentation, treatment and outcomes of childhood UTI caused by ESBL-PE in Europe.

Methods: Multicenter retrospective cohort study. Children 0 to 18 years of age with fever, positive urinalysis and positive urine culture for an ESBL-PE uropathogen, seen in a participating hospital from January 2016 to July 2017, were included.

Main outcome measures: Primary outcome measure: day of defervescence was compared between (1) initial microbiologically effective treatment (IET) versus initial microbiologically ineffective treatment (IIT) and (2) single initial antibiotic treatment versus combined initial antibiotic treatment.

Secondary outcome measures: Clinical and microbiologic failure of initial treatment.

Results: We included 142 children from 14 hospitals in 8 countries. Sixty-one children had IET and 77 IIT. There was no statistical difference in time to defervescence for effective/ineffective groups (P = 0.722) and single/combination therapy groups (P = 0.574). Two of 59 (3.4%) and 4/66 (6.1%) patients exhibited clinical failure during treatment (P = 0.683) when receiving IET or IIT, respectively. Eight of 51 (15.7%) receiving IET and 6/58 (10.3%) receiving IIT patients (P = 0.568) had recurring symptoms/signs suggestive of a UTI. Recurrence of a UTI occurred 15.5 days (interquartile range, 9.0-19.0) after the end of treatment.

Conclusions: Time to defervescence and clinical failure did not differ between IET/IIT groups. Non-carbapenem beta-lactam antibiotics may be used for the empiric treatment of ESBL febrile UTIs, until susceptibility testing results become available.

PubMed Disclaimer

References

    1. Centers for Disease Control and Prevention. Office of Infectious Disease Antibiotic Resistance Threats in the United States, 2013. 2013. Available at: http://Www.Cdc.Gov/Drugresistance/Threat-Report-2013. Accessed March 31, 2019.
    1. World Health Organization. Antimicrobial Resistance: Global Report on Surveillance. 2014. Available at: http://Www.Who.Int/Drugresistance/Documents/Surveillancereport/En. Accessed March 31, 2019.
    1. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657–686.
    1. Pana ZD, Zaoutis T. Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?. F1000Research. 2018;7:1347.
    1. Hsu AJ, Tamma PD. Treatment of multidrug-resistant Gram-negative infections in children. Clin Infect Dis. 2014;58:1439–1448.

MeSH terms